|
7 Companies |
|
4 Products |
|
4 Products |
|
7 Mechanisms of Action |
|
0 Trials |
|
25 News |
|
- ||||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial completion: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Nov 23, 2016
P3, N=184, Completed, Sponsor: Merz Pharmaceuticals GmbH
Active, not recruiting --> Completed
- |||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial primary completion date: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Sep 28, 2016
P3, N=184, Active, not recruiting, Sponsor: Merz Pharmaceuticals GmbH
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Aug 2015
- | tropicamide / Generic mfg.
Trial completion: Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients (clinicaltrials.gov) - Dec 12, 2015
P2, N=30, Completed, Sponsor: NeuroHealing Pharmaceuticals Inc.
Trial primary completion date: Nov 2015 --> Aug 2015 Active, not recruiting --> Completed
- | tropicamide / Generic mfg.
Trial completion: NH004-2: Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients (clinicaltrials.gov) - Oct 14, 2015
P2, N=19, Completed, Sponsor: NeuroHealing Pharmaceuticals Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment closed: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Aug 28, 2015
P3, N=180, Active, not recruiting, Sponsor: Merz Pharmaceuticals GmbH
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial primary completion date: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Aug 22, 2015
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Dec 2015
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion, Enrollment change, Trial primary completion date: ALS-TOX: Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea (clinicaltrials.gov) - Aug 14, 2015
P2, N=18, Completed, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Jul 2015 --> Dec 2015 Recruiting --> Completed | N=90 --> 18 | Trial primary completion date: Aug 2015 --> Mar 2014
- Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment change, Trial withdrawal: Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 12, 2015
P2, N=0, Withdrawn, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Completed | N=90 --> 18 | Trial primary completion date: Aug 2015 --> Mar 2014 N=20 --> 0 | Recruiting --> Withdrawn
- | tropicamide / Generic mfg.
Enrollment closed, Trial primary completion date: Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients (clinicaltrials.gov) - Aug 12, 2015
P2, N=36, Active, not recruiting, Sponsor: NeuroHealing Pharmaceuticals Inc.
N=20 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Oct 2015
- Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial completion, Enrollment change: Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism (clinicaltrials.gov) - Jan 28, 2015
P2, N=10, Completed, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Oct 2015 Recruiting --> Completed | N=20 --> 10
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial primary completion date: ALS-TOX: Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea (clinicaltrials.gov) - Jan 17, 2015
P2, N=90, Recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed | N=20 --> 10 Trial primary completion date: Aug 2014 --> Aug 2015
- |||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial primary completion date: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Nov 5, 2014
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Apr 2015 --> Jul 2015
- || metoclopramide / Generic mfg., clozapine / Generic mfg.
New P3 trial: Metoclopramide as Treatment of Clozapine-induced Hypersalivation (clinicaltrials.gov) - Aug 21, 2014
P3, N=61, Completed, Sponsor: Beersheva Mental Health Center
- Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial primary completion date: Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism (clinicaltrials.gov) - Jul 18, 2014
P2, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Apr 2015 --> Jul 2015 Trial primary completion date: Nov 2013 --> Oct 2014
- ||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial initiation date: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Apr 28, 2014
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
Trial primary completion date: Nov 2013 --> Oct 2014 Initiation date: Mar 2014 --> Apr 2014
- |||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment open: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Apr 28, 2014
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- Clinical: Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service (clinicaltrials.gov) - Apr 1, 2014
P=N/A, N=65, Completed, Sponsor: Mahidol University
- |||||||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
New P3 trial: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Mar 17, 2014
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
- | tropicamide / Generic mfg.
New P2 trial: Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients (clinicaltrials.gov) - Apr 29, 2013
P2, N=36, Recruiting, Sponsor: NeuroHealing Pharmaceuticals Inc.
- | clonidine/oxybutynin (OP-014) / Orient Europharma
Trial completion: A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease (clinicaltrials.gov) - Sep 20, 2012
P2, N=24, Completed, Sponsor: Orient Pharma Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- Xeomin (incobotulinumtoxinA) / Merz Pharma
New P2 trial: Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism (clinicaltrials.gov) - Jul 26, 2012
P2, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
- Xeomin (incobotulinumtoxinA) / Merz Pharma
New P2 trial: Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 25, 2012
P2, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
- Myobloc (rimabotulinumtoxin B) / Supernus Pharma, Eisai
Trial completion: Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 12, 2012
P2/3, N=20, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Completed Active, not recruiting --> Completed
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P2 trial: ALS-TOX: Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea (clinicaltrials.gov) - Mar 11, 2012
P2, N=90, Recruiting, Sponsor: Hospices Civils de Lyon
- New P1 trial: Bioavailability of Vagantin (clinicaltrials.gov) - Aug 31, 2011
P1, N=12, Completed, Sponsor: University Medicine Greifswald